{"name":"Aravive","slug":"aravive","ticker":"ARAV","exchange":"NASDAQ","domain":"aravive.com","description":"Aravive is a clinical-stage oncology company focused on developing novel therapies for patients with cancer. The company's lead product candidate, odronate, is being investigated for the treatment of various cancers, including clear cell ovarian cancer and pancreatic cancer. Aravive has a strong pipeline of product candidates in development, with a focus on addressing unmet medical needs in oncology. The company is headquartered in Houston, Texas, and is listed on the NASDAQ stock exchange under the ticker symbol ARAV.","hq":"Houston, TX","founded":0,"employees":"","ceo":"Gail McIntyre","sector":"Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$55M","metrics":{"revenue":40000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":11075000,"netIncome":-76322000,"cash":62153000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Odronate patent cliff ($0.0B at risk)","drug":"Odronate","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Paclitaxel (Pac)","genericName":"Paclitaxel (Pac)","slug":"paclitaxel-pac","indication":"Metastatic carcinoma of the ovary","status":"marketed"}]}],"pipeline":[{"name":"Paclitaxel (Pac)","genericName":"Paclitaxel (Pac)","slug":"paclitaxel-pac","phase":"marketed","mechanism":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic carcinoma of the ovary","Breast cancer (metastatic and adjuvant)","Non-small cell lung cancer","Kaposi's sarcoma","Gastric adenocarcinoma"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Aravive Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Aravive reported its fourth quarter and full year 2023 financial results, with a net loss of $24.5 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-06","type":"deal","headline":"Aravive Announces Collaboration with Merck to Develop Odronate in Combination with KEYTRUDA","summary":"Aravive announced a collaboration with Merck to develop odronate in combination with KEYTRUDA for the treatment of various cancers.","drugName":"","sentiment":"positive"},{"date":"2023-08-07","type":"trial","headline":"Aravive Announces Positive Interim Results from Phase 1/2 Clinical Trial of Odronate in Patients with Clear Cell Ovarian Cancer","summary":"Aravive announced positive interim results from a Phase 1/2 clinical trial of odronate in patients with clear cell ovarian cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9XNE1HSGE3U0U1Q3l4OG1SeFk5UWpSd0d4TnZDRlRqamhhRjJacXB6M01SbUt2VEgzRTNCYVk2eWFrb1FDTFBwd0JURGhaZ1lzdEFzMXV3c1JrMzFoMHRr?oc=5","date":"2019-12-22","type":"pipeline","source":"ChartMill","summary":"ARAV Stock Price, Quote & Chart | Aravive Inc (NASDAQ:ARAV) - ChartMill","headline":"ARAV Stock Price, Quote & Chart | Aravive Inc (NASDAQ:ARAV)","sentiment":"neutral"}],"patents":[{"drugName":"Odronate","drugSlug":"odronate","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","Bayer","Merck & Co."],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":40000000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":40000000,"period":"2017-12-31"},{"value":40000000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11075000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-76322000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":62153000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}